Follow-up: Tirzepatide's shorter half-life and its one practical consequence posts 61–90

Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.

The step people skip is the one I have spelled out.

Post #74 and I disagree about the size of the effect, not about the direction.

Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.

The conclusion is tentative; the arithmetic underneath it is not.

Narrowing post #76, because the general version has more than one answer.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

I would rather say I do not know than round it up to an answer.

Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.

Fine by me. I had wanted a stronger conclusion and there is not one available.

Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.

Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.

Noting that I have skin in this question and have tried to discount for it.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

That is what I would do. It may not be what is correct.

On post #80 — agreed on the reasoning, with one qualification.

Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.

Agreed on all of that, and I have nothing to add to it.

Content versus purity applies here as everywhere: a lyophilised vial can be highly pure and contain less peptide than the label states, because the balance of the mass is water, counter-ion and excipient.

Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.

That is the shape of it. The detail is where I would expect to be corrected.

This follows post #87 rather than contradicting it.

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

Acknowledging rather than arguing. The reasoning holds as far as I can follow it.

Post #87 answers the question as asked. The question underneath it is different.

Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.